About: Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study
Creator	Darman, ; Jarahzadeh, Hossein Mohammad, 23 Sadri, 15 Shamsi Okati, 18
Source	Elsevier; Medline; PMC
abstract	Since Dec. 2019 the new coronavirus (SARS-CoV-2) has infected millions and claimed life of several hundred thousand worldwide. However, so far no approved vaccine or drug therapy is available for treatment of virus infection. Convalescent plasma has been considered a potential modality for COVID-19 infection. One hundred eighty-nine COVID-19 positive patients including 115 patients in plasma therapy group and 74 patients in control group, registered in the hospitals with confirmed COVID-19 infection, entered this multi-center clinical study. Comparison of outcomes including all-cause mortality, total hospitalization days and patients’ need for intubation between the two patient groups shows that total of 98 (98.2 %) of patients who received convalescent plasma were discharged from hospital which is substantially higher compared to 56 (78.7 %) patients in control group. Length of hospitalization days was significantly lower (9.54 days) in convalescent plasma group compared with that of control group (12.88 days). Only 8 patients (7%) in convalescent plasma group required intubation while that was 20 % in control group. This clinical study provides strong evidence to support the efficacy of convalescent plasma therapy in COVID-19 patients and recommends this treatment for management of these patients. Clinical efficacy, immediate availability and potential cost effectiveness could be considered as main advantages of convalescent plasma therapy.
has issue date	2020-07-15(xsd:dateTime)
bibo:doi	10.1016/j.transci.2020.102875
bibo:pmid	32694043
has license	no-cc
sha1sum (hex)	94bf2841cedb80040f6a6754b1d254132683a781
schema:url	https://doi.org/10.1016/j.transci.2020.102875
resource representing a document's title	Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study
has PubMed Central identifier	PMC7362821
has PubMed identifier	32694043
schema:publication	Transfus Apher Sci
resource representing a document's body	covid:94bf2841cedb80040f6a6754b1d254132683a781#body_text
is schema:about of	named entity 'therapy' named entity 'Supervision' named entity 'Plasma' named entity 'Majid' named entity 'Writing' named entity 'claimed' named entity 'infection' named entity 'COVID-19' named entity 'plasma' named entity 'COVID' named entity 'coronavirus' named entity 'SARS-CoV-2' named entity 'control group' named entity 'virus' named entity 'CT scan' named entity 'convalescent plasma' named entity 'viral infections' named entity 'clinical study' named entity 'COVID' named entity 'convalescent plasma' named entity 'convalescent plasma' named entity 'antibodies' named entity 'all-cause mortality' named entity 'case control' named entity 'antiviral medications' named entity 'mechanical ventilation' named entity 'Iran' named entity 'all-cause mortality' named entity 'lung lobes' named entity 'Convalescent plasma' named entity 'treatment group' named entity 'immune response' named entity 'infection' named entity 'MERS' named entity 'treatment group' named entity 'Demographic information' named entity 'COVID' named entity 'Iran' named entity 'transfusion' named entity 'supportive care' named entity 'COVID' named entity 'convalescent plasma' named entity 'COVID' named entity 'qRT-PCR' named entity 'Convalescent plasma' named entity 'COVID' named entity 'control group' named entity 'convalescent plasma' named entity 'plasma' named entity 'Lopinavir/Ritonavir' named entity 'lung' named entity 'plasma' named entity 'vaccine' named entity 'convalescent plasma' named entity 'convalescent plasma' named entity 'COVID' named entity 'viral illnesses' named entity 'continuous variable' named entity 'health care' named entity 'convalescent plasma' named entity 'treatment group' named entity 'survival rate' named entity 'control group' named entity 'oxyhemoglobin' named entity 'tested positive' named entity 'Convalescent plasma therapy' named entity 'anti-viral drug' named entity 'transfusion' named entity 'respiratory support' named entity 'COVID' named entity 'convalescent plasma' named entity 'Qom' named entity 'Ebola' named entity 'COVID-19 pandemic' named entity 'Fisher's Exact test' named entity 'infection' named entity 'administrated'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software